In Situ Hybridization Market – Revenue Growth in Expected at a CAGR of 7.4%

Overview of This Research:

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global in situ hybridization market.

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the ISH market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.

Expected Revenue Growth:

The global in situ hybridization market size is projected to reach USD 1.3 billion by 2025 from USD 0.9 billion in 2020, at a CAGR of 7.4% during the forecast period. 

Download PDF Brochure@

Major Growth Boosters:

The increasing incidence of cancer and genetic disorder and awareness of ISH based companion diagnostics tests are the major factors driving the growth of this market.

Hospitals & diagnostic laboratories accounted for the fastest-growing end user segment of the ISH market

Based on the end user, the in situ hybridization market is segmented into hospital & diagnostic laboratories, academic & research institutes, CROs, and pharmaceutical & biotechnology companies. The hospital & diagnostic laboratories segment accounted for the largest share of the ISH market in 2019. This can be attributed to the increasing number of molecule-based screening, increasing number of specialty diagnostic tests performed in hospital laboratories, the rising number of in-house diagnostic procedures, and the rising trend of establishing in-house diagnostic capabilities in hospitals.

Recent Developments:

In 2020, RNAscope ISH Detection Kit (Bio-Techne) received CE-IVD approval for BOND-III platform (Leica Biosystems ).

In 2020, Creative Bioarray (US) launched 2019 Novel Coronavirus Detection FISH probes to detect viral particles in infected cells & tissues.

In 2019, Roche launched VENTANA HER2 Dual ISH DNA Probe Cocktail assay.

In 2019, Roche provided its platform for integration with Bio-Techne’s RNAscope ISH assay.

In 2019, Agilent Technologies, the National University of Singapore, and the National University Hospital set up Singapore’s first integrated R&D facility.

North America accounted for the largest share of the ISH market

North America accounted for the largest share of the global market, followed by Europe. The large share of the North American region can be attributed to the presence of major players operating in the ISH market in the US, the rising incidence of cancer and infectious diseases, and the increasing adoption of CDx assay kits.

Request Sample Pages@

Major Industry Players:

The prominent players operating in the ISH market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), and Danaher Corporation (US).